# Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors

> **NCT00115128** · — · COMPLETED · sponsor: **Amgen** · enrollment: 309 (actual)

## Conditions studied

- Normal PBPC Donors

## Interventions

- **DRUG:** filgrastim

## Key facts

- **NCT ID:** NCT00115128
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2007-05
- **Final completion:** 2007-09
- **Target enrollment:** 309 (ACTUAL)
- **Last updated:** 2013-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115128, "Open-Label Trial of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Filgrastim in Normal Donors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00115128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*